T cell activation and effector function is characterized by changes in metabolism. Altered metabolism is common to almost all types of activated T cells, but fatty acid synthesis seems to especially drive the formation of Th17 cells. Indeed, research has demonstrated that inhibition of early fatty acid synthesis through targeting of acetyl-CoA carboxylase (ACC1) can inhibit Th17 cell formation and instead promote the generation of regulatory T cells. Fatty acid synthase (FASN) is downstream of ACC, and previous studies have shown that FASN activity influences both cancer and inflammation. However, it remains to be determined whether FASN is a viable target for inhibiting Th17 cell function. Here, we demonstrate that FASN is a critical metabolic control for the generation of inflammatory subsets of Th17 cells. Conversely, inhibiting FASN function promotes IFN-g production by Th1 and Th1-like Th17 cells. In vivo, inhibition of FASN, specifically in Th17 cells, leads to reduction of experimental autoimmune encephalomyelitis disease. These studies demonstrate the necessity of FASN in the autoimmune inflammatory function of Th17 cells.
Introduction
Altered metabolism and de novo FAS are important for both CD4 + and CD8 + T cell effector fates. Activation through the TCR leads to an increase of aerobic glycolysis, the induction of mTOR, and FAS [1] [2] [3] . This increase of aerobic glycolysis, an effect first observed in cancer cells and known as the Warburg effect, results in shifting T cell metabolism toward biomolecule production [1, 2, 4] . Shifting metabolism contributes to T cell proliferation and signaling [5, 6] . Moreover, ACC1, the rate-limiting enzyme necessary for FAS, is necessary for the differentiation of Th17 cells [7, 8] .
FASN is the multienzyme complex that mediates the conversion of acetyl-CoA and malonyl-CoA to saturated longchain fatty acids [9] . Those fatty acids can be further modified and used for cellular processes, such as membrane formation and posttranslational protein modification [7, 9, 10] . The specific FASN inhibitor C75 is effective in inhibiting tumor growth in numerous cancer models [11] [12] [13] . Whether FASN is important for Th17 effector function in comparison to other CD4 + Th subsets remains to be determined. However, FASN acts downstream of ACC1 during FAS [1] , suggesting that FASN could also be an attractive therapeutic target for abrogating Th17 cell activity.
Th17 cells, characterized by the expression of IL-17 and the transcription factor RORgt, have important roles in mucosal host defense as well as in autoimmunity [14] [15] [16] [17] . Th17 cells and IL-17 production are particularly damaging in models of inflammatory autoimmune disease [18, 19] . Moreover, autoreactive Th17 cells can become "pathogenic" when their TCR recognizes cognate Ag in the presence of the cytokines IL-1b and IL-23 [18, [20] [21] [22] [23] [24] . Those cells express high levels of IL-17 but also gain expression of GM-CSF and IFN-g, which are believed to contribute to pathogenic Th17 cell effector function.
Previous studies have shown inhibition or deletion of ACC1 reduces Th17 cell generation and skews differentiation toward T regs [7, 8] . Inhibition of FASN was also shown to lessen DSSinduced colitis severity in mice [25] . The influence of FAS on Th17 pathogenicity downstream of ACC1, however, is unknown. Herein, we show that FASN is instrumental for the establishment of proinflammatory Th17 cells. Inhibition of FASN with a synthetic inhibitor of FASN-C75-resulted in a reduction of IL-17 production and, instead, promoted IFN-g expression in CD4 + T helper cells. In vivo, specifically targeting FASN in Th17 cells results in dramatic decreases of IL-17 expression as well as reduced incidence and severity of EAE.
MATERIALS AND METHODS

Mice
C57BL/6 and Rag1
2/2 mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). IL-17F RFP mice have been previously described [26] .
All mice procedures were carried out under approval of the institutional animal care and use committee at Rosalind Franklin University of Medicine and Science.
T cell culture
For T cell differentiation, naive cells were sorted from secondary lymphoid organs on a BD Biosciences (Franklin Lakes, NJ, USA) FACS ARIAII as a CD4 + CD62L hi CD25 2 CD44 2 population, as described previously [27] . Th17 cultures included 20 ng/ml mIL-6 and 3 ng/ml mouse TGF-b or 20 ng/ml mouse IL-1b, 20 ng/ml mouse IL-6, and 25 ng/ml mouse IL-23 (R&D Systems, Minneapolis, MN, USA). Th1 cells were generated using 30 U/ml human IL-2 (PeproTech, Rocky Hill, NJ, USA) and 15 ng/ml mouse IL-12 (R&D Systems), and T reg cells were generated with 30 U/ml human IL-2 and 15 ng/ml mouse TGF-b. T cell cultures were also stimulated with or without 2 mg/ml Pam3CSK4 (InvivoGen, San Diego, CA, USA). For effector conversion assays, Th17 cells were generated, as described, with IL-6 and TGF-b for 5 d. recipient mice. EAE development and progression was assessed on a 1-5 scale, as previously described [29] . At the experimental endpoint, mice were perfused, and brain, spinal cord, and spleen samples were isolated from individual mice. CNS tissues were analyzed for CD4, CD11b, IL-17, IFN-g, and GM-CSF expression (eBioscience) by flow cytometry. Splenocytes were plated at 1 3 10 6 cells/ml and then restimulated with increasing concentrations of MOG . Supernatants were collected after 3 d and analyzed for IL-17 and IFN-g production by ELISA (BD Biosciences).
Quantitative PCR
mRNA was isolated by lysing cells in TRIzol (Thermo Fisher Scientific). cDNA was synthesized using the Moloney murine leukemia virus system per manufacturer's protocol (Thermo Fisher Scientific). Real-time PCR was performed with SYBR green on an Applied Biosystems 7500 Real Time System (Thermo Fisher Scientific). All genes were normalized to the expression of actin. Primer sequences for the genes analyzed are listed in the Supplemental Materials.
Statistics
Statistics were performed using 1-way ANOVA, 2-way ANOVA, or paired t tests, as described. P values , 0.05 were considered statistically significant.
RESULTS AND DISCUSSION
TLR2-or IL-23-stimulated Th17 cells express high FASN
We previously reported that activation of Th17 cells through TLR2 induces robust proliferation and higher IL-17 production. Consequently, TLR2-deficient Th17 cells are defective at inducing EAE [29] . Others have shown that treating Th17 cells with IL-23 and IL-1b during differentiation induces a subset of "pathogenic" Th17 cells that are especially damaging for autoimmune inflammation [20] [21] [22] 30] . Increased aerobic glycolysis is associated with the differentiation of effector T cells [3] and FAS through ACC1 is favorable for Th17 generation but inhibitory toward T reg differentiation [7, 8] . Therefore, we determined whether the downstream FASN enzyme was present in inflammatory vs. noninflammatory subsets of Th17 cells. Western blot analysis demonstrated that FASN was induced in differentiating Th17 cells compared with naive CD4 + T cell controls ( Fig. 1A) , suggesting that FAS is accelerated, as demonstrated for ACC1 [7, 8] . However, we also observed that driving Th17 cells toward a more inflammatory subset with either IL-23 and IL-1b ( and ATP-citrate lyase (ACL; Acly) [1] , both of which were increased in Th17 cells compared with naive control. However, only the expression of Fasn was further induced in Th17 cells upon stimulation with Pam3CSK4. Therefore, in addition to ACC1 [7] , FASN is also enhanced in Th17 cells and can be further induced with proinflammatory stimulation.
FASN inhibition reduces Th17 differentiation
To determine the effect of FASN on CD4 + T cell differentiation, we treated cells with increasing doses of C75, a specific inhibitor of FASN [13] . We found that a low dose (1 mM) of C75 had a negligible effect on Th17 differentiation; however, higher concentrations of C75 ($5 mM) impaired IL-17 production ( Fig.  2A) , which is consistent with a previous report using 10 mM C75 [8] . Th1 cell differentiation was unaffected by a low dose, whereas those cells conversely expressed more IFN-g with a high (10 mM) dose ( Fig. 2A) . Inhibiting FASN during T reg differentiation did not lead to significant differences in FoxP3 expression under either optimal or suboptimal conditions (Supplemental Fig. 1A and B) , which was surprising considering that ACC1 influences the Th17/T reg balance [7, 8] . Thus, there may be regulatory pathways important for T reg development that originate with ACC1 but are not similarly controlled at the downstream FASN level. We further examined differentiation on T cells transduced with shRNA specific for FASN (Supplemental Fig. 1C ). Similar to our results with C75, we found that silencing FASN decreases Th17 generation, increases Th1 generation, and has a negligible effect on T reg differentiation (Fig. 2B) . Collectively, those data suggested that FASN and de novo synthesis of fatty acids selectively promoted Th17 differentiation.
Treatment of Th17 cells with a high dose of C75 (.10 mM) led to a decrease of proliferation, which was consistent with increased glycolysis during T cell activation [1] . Indeed, we thought it plausible that the decreased Th17 generation observed after FASN inhibition ( Fig. 2A) was at least partially due to lineagespecific reductions in proliferation or viability. To investigate, we first analyzed proliferation in Th17 cells that were stimulated with increasing concentrations of C75 and found that only high doses ($10 mM) inhibited proliferation (Supplemental Fig. 2A ). Likewise, a 10-mM C75 treatment also substantially reduced viability in Th17 cells polarized with TGF-b and IL-6 (Supplemental Fig.  2B ) but did not affect Th1 cell viability and had only a modest effect on Th17 cells polarized with IL-1b, IL-6, and IL-23. shRNA knockdown had little effect on viability (Supplemental Fig. 2C ), suggesting that a minimum level of FASN activity is needed specifically for Th17 cells to survive and proliferate, whereas 10 mM C75 may abrogate this minimal activity. However, we did also find that 5 mM of C75 or shRNA knockdown of FASN decreased IL-17 expression without adversely affecting viability, indicating that FASN may also regulate Th17 cell differentiation. That was supported by another study demonstrating that ACC1 regulates the binding of RORgt (Th17 cell-specific transcription factor) to the Il17 promoter [8] . Because ACC1 is intact in those cells, it remains to be determined whether FASN performs a similar function upstream of ACC1.
Next, we examined whether FASN activity regulated the differentiation of the more-inflammatory subsets of Th17 cells. Naive CD4 + T cells were cultured under Th17-polarizing conditions in the absence or presence of 5 mM C75 and/or Pam3CSK4. We found that Pam3CSK4 treatment induced greater IL-17 production in those cells, as anticipated (Fig. 2C ) [29] . C75 treatment, however, reduced the TLR2-dependent effect slightly more compared with C75-treated controls (23 vs. 15% IL-17 reduction, respectively). However, 5 mm of C75 had no influence on Pam3CSK4-mediated proliferation or viability (data not shown). Polarizing Th17 cells with IL-1b, IL-6, and IL-23 in the presence of C75 or FASN shRNA also reduced the frequency of IL-17-expressing cells (Supplemental Fig. 3A and  B) . The induction of GM-CSF (protein) was not influenced by FASN silencing; however, mRNA analysis revealed that the transcription of both the Csf2 and Rorc genes was reduced in cells expressing FASN shRNA (Supplemental Fig. 3C ). Overall, those data suggest that increased FASN activity may help drive the differentiation of inflammatory Th17 cell subsets and that FASN may be linked to RORgt expression and may function similar to ACC1 [8] .
FASN activity regulates the effector potential of Th17 cells
Given the up-regulation of FASN observed in inflammatory Th17 cells (Fig. 1) , we thought it likely that FASN regulates effector Th17 cell function as well. Restimulating differentiated Th17 cells in the presence of IL-12 or IL-23 converts cells to an inflammatory phenotype characterized by IFN-g expression and EAE pathogenicity [24, [30] [31] [32] . Thus, we polarized naive CD4 + T cells to Th17 cells for 5 d, followed by 3 d of restimulation in the absence or presence of IL-12, IL-23, Pam3CSK4, and/or 5 mM C75. Th17 cells that were restimulated with IL-12 gained IFN-g as anticipated; however, the addition of C75 led to even more IFN-g expression (Fig. 3) , consistent with our results on Th1 cells (Fig. 2) . Conversely, cells that were restimulated with IL-23 or Pam3CSK4 exhibited a sharp loss of IL-17 with C75 treatment (Fig. 3) . The modest gains of IL-17 expression observed in IL-12-treated and gains of IFN-g observed in IL-23-or Pam3CSK4-treated cells were consistent but did not reach statistical significance across multiple experiments. GM-CSF expression in all cultures was unaffected by C75 (data not shown). Surprisingly, all of the cultures treated with C75 showed slightly increased viability (Supplemental Fig. 4 ), which may be indicative of the adoption of a Th1-like phenotype (e.g., IFN-g expression) that is not sensitive to FASN inhibition ( Fig. 2A and Supplemental Fig. 2B ). Overall, these results indicate that FASN specifically regulates IL-17 production in effector Th17 cells.
Additional experiments demonstrated that FASN inhibition with 5 mM of C75 only during primary differentiation failed to result in a substantial decrease of IL-17 after secondary restimulation; however, the addition of C75 only to the restimulation culture resulted in a decrease of IL-17 (Supplemental Fig. 5A ). We also found that effector cells stimulated with IL-12, IL-23, or Pam3CSK4 further up-regulated FASN (Supplemental Fig.  5B ). Overall, these results demonstrate that FASN activity is important for proliferation and survival during Th17 differentiation and for IL-17 production by effector Th17 cells. How FASN specifically contributes to the expression of IL-17 rather than other cytokines (e.g., IFN-g) remains to be determined. We did not observe evidence of an alternative fate because the expression of other lineage-specific transcription factors, such as FoxP3 (Supplemental Fig. 1A and B) , GATA binding protein 3 (data not shown), and T-bet (T box transcription factor Tbx21; data not shown), were unchanged with C75 treatment during primary Th17 differentiation. Alternatively, FASN may be directly or indirectly regulating transcription of the Th17 genetic program, similar to ACC1 [8] , and future experiments will be necessary to determine the mechanism underlying the regulation of Th17 function by FASN.
Targeted FASN inhibition in Th17 cells reduces EAE severity
Next, we investigated the effect of FASN inhibition on Th17 effector function in vivo using the EAE model. Previous work demonstrated that i.p. administration of C75 during DSSinduced colitis reduced disease symptoms [25] . However, it remains to be determined what cellular target(s) of FASN inhibition were responsible. To investigate the role of FASN solely in Th17 cells, we performed adoptive transfer EAE experiments as described [28] . IL-17F +/RFP mice were the source of donor T cells because of reliable reporting of Th17 cells as well as the dispensability of IL-17F for EAE [26] . These mice were immunized with MOG 35-55 in an emulsion with CFA for 7 d, followed by the harvesting of spleen and draining lymph nodes. Tissue was then homogenized, and cells were expanded with MOG 35-55 and IL-23 for 6 d to drive the formation of Ag-specific pathogenic effector Th17 cells. After expansion, CD4 + T cells were isolated and cultured for 2 d in the absence or presence of 5 mM C75, and then, RFP + Th17 cells were sorted and injected into Rag1 2/2 recipient mice. Analysis immediately before transfer into Rag1 2/2 recipients demonstrated that the expanded RFP + cells cultured with C75 had no initial defects in viability and either IL-17 or IFN-g expression (Supplemental Fig. 6 ), in contrast with our in vitro effector experiments (Fig. 3) . The reason for this discrepancy has yet to be identified, but we think that the expansion stimuli (8 d priming, followed by 6 d expansion with IL-23) were too potent to observe cytokine differences with a C75 treatment of only 2 d. Furthermore, the use of the reporter system only selects for the most-robust Th17 cells.
After expansion, equal numbers of RFP + Th17 cells were injected into Rag1 2/2 mice to induce EAE. We found that recipient mice receiving Th17 cells that were pretreated with C75 had both a lower disease incidence and severity compared with mice receiving Th17 cells treated only with vehicle (Fig.  4A) . Cellularity of both the spleen and CNS tissues in those animals was equivalent between the 2 groups (Fig. 4B) , which indicates that C75-treated cells survived and proliferated comparable to the controls after transfer. Infiltration analysis revealed that mice receiving C75-treated Th17 cells did have a modest but statistically significant reduction in the frequency of CD4 + T cells in the CNS (Fig. 4C) . The presence of CD4 + T cells in the CNS, however, does demonstrate that FASN inhibition had a negligible effect on the ability of those cells to migrate and infiltrate the CNS.
To further understand the mechanism behind our findings, we analyzed encephalitogenic cytokine production in the CNS and spleens of diseased animals. Within the CNS, we found that pretreatment of C75 eventually led to a reduction of IL-17 expression ( Fig. 4D and E) . The frequency of IFN-g + and IFN-g + IL-17 + CD4 + T cells infiltrating the CNS was unchanged between the 2 groups, which was surprising, considering that Th17 cells that convert to a Th1-like phenotype (IFN-g expression) are believed to be the most pathogenic for EAE [32] . However, that result was consistent with our in vitro data demonstrating that FASN inhibition did not reduce IFN-g production by Th1 (Fig. 2) or effector Th17 cells (Fig. 3) . GM-CSF expression was unchanged between the 2 groups (data not shown). Ag-specific T cells derived from the spleen were restimulated with MOG 35-55 , and a similar trend was observed in which IL-17 production was decreased with FASN inhibition, whereas differences in IFN-g did not reach statistical significance (Fig. 4F) . In summary, we found that inhibition of FAS through targeting of FASN can reduce the inflammatory potential of Th17 cells. In vitro, we tested that ability of C75 to inhibit Th1 differentiation but observed enhanced IFN-g expression at high C75 doses. Th17 cells were much more sensitive to C75, suggesting that the activity of FASN is specifically linked to Th17 generation and effector function. Although Th17 cells produce IL-17, other reports have demonstrated that Th17-derived IFN-g and GM-CSF are what makes a Th17 cell pathogenic for autoimmune inflammation [21, 22, 32] . However, only the expression of IL-17 seems to be affected by FASN inhibition in our model. That finding may indicate that the activity of FASN is alternatively required for an unidentified effector function of Th17 cells, which is regulated in parallel to IL-17 expression. Although our findings in the EAE model show that IL-17-expressing T cells in the CNS are moderately reduced with C75 treatment, the dramatic differences observed in EAE disease incidence and severity strongly suggest that other mechanisms outside of IL-17, IFN-g, or GM-CSF production are contributing to that phenotype. Future experiments will be necessary to understand the mechanisms underlying the role of FASN in inflammatory Th17 cells.
A previous report showed that treatment of mice with C75 during DSS-induced colitis could reduce disease [25] . However, it remains to be determined which cells are most sensitive to the anti-inflammatory effects of FASN inhibition. Here, we demonstrated that targeting Th17 cells alone with the FASN inhibitor was sufficient to reduce EAE disease severity. Furthermore, we used only a single dose at a concentration (5 mM) that appears to be nontoxic to T cells because their viability and proliferative capacity was found to be intact in multiple experiments. Pharmacologic inhibition of ACC1 is similarly effective at reducing EAE disease, which includes a reduction of IL-17-producing cells in the CNS [7, 8] . However, there are discrepancies in those reports regarding the necessity of ACC1 in regulating IFN-g expression in the CNS during EAE. Our data suggest that FASN is predominately important for IL-17, rather than IFN-g, expression when Th17 cells are directly targeted in the EAE model. Further studies will be needed to understand the various functions of FASN in different Th cell subsets, but our findings may have implications for future therapies in autoimmune diseases based solely on targeting inflammatory Th17 cells. 
